Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-01-18
2005-01-18
Fredman, Jeffrey (Department: 1637)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024300, C435S006120
Reexamination Certificate
active
06844432
ABSTRACT:
The present invention relates to a method for diagnosing panic disorder, said method being based on the determination of the class of polymorphism of the short tandem repeat (STR) complex in the upstream region of human cholecystokinin gene. The polymorphic DNA comprises a DNA sequence, having a general formula (1):in-line-formulae description="In-line Formulae" end="lead"?5′(GGAA)n1X(GGAG)n2(GGAA)n3(GGGA)n4GAG(AGAC)n5Y(GGAA)n63′ (1)in-line-formulae description="In-line Formulae" end="tail"?wherein X denotes a DNA sequence of SEQ ID NO: 1, Y denotes a DNA sequence of SEQ ID NO:2 and each of n1, n2, n3, n4, n5 and n6 denotes independently 0 or a positive integral number, whereby said DNA ranging from 363 to 399 base pairs in length. The invention also relates to an assay kit used for implementing said method.
REFERENCES:
patent: 5474796 (1995-12-01), Brennan
Genbank AC018358[gi:6554213] , Dec. 12, 1999.*
Genbank AC018358[gi31126629], May 29, 2003.*
Bowen et al. “Linked Polymorphisms Upstream of Exons 1 and 2 of the Human Cholecystokinin Gene Are Not Associated with Schizophrenia or Bipolar Disorder” Molecular Psychiatry 3:67-71 (1998).
Bradwejn et al. “Cholecystokinin-Tetrapeptide Induces Panic Attacks in Patients with Panic Disorder” Can. J. Psychiatry 35:83-85 (1990).
Bradwejn et al. “Enhanced Sensitivity to Cholecystokinin Tetrapeptide in Panic Disorders—Clinical and Behavioral Findings” Arch. Gen. Psychiatry 48:603-610 (1991).
Bradwejn et al. “The Panicogenic Effects of Cholecystokinin-Tetrapeptide Are Antagonized by L-365,260, A Central Cholecystokinin Receptor Antagonist, in Patients With Panic Disorder” Arch. Gen. Psychiatry 51:486-493 (1994).
De Montigny et al. “Cholecystokinin Tetrapeptide Induces Panic-like Attacks in Healthy Volunteers” Arch Gen Psychiatry 46:511-517 (1989).
De Weerth et al. “Molecular Cloning, Functional Expression and Chromosomal Localization of the Human Cholecystokinin Type A Receptor” Biochemical and Biophysical Research Communications 194(2):811-818 (1993).
Hattori et al. “Identification of a Compound Short Tandem Repeat Stretch in the 5'-Upstream Region of the Cholecystokinin Gene, and Its Association with Panic Disorder but Not with Schizophrenia” Molecular Psychiatry 6:465-470 (2001).
Hökfelt et al. “Evidence for Coexistence of Dopamine and CCK in Meso-Limbic Neurones” Nature 285:476-478 (1980).
Moroji et al. “Antipsychotic Effects of Ceruletide (Caerulein) on Chronic Schizophrenia” Arch. Gen. Psychiatry 39:485-486 (1982).
Rasmussen et al. “Cholecystokinin (CCK) and Schizophrenia: The Selective CCKBAntagonist LY262691 Decreases Midbrain Dopamine Unit Activity” European Journal of Pharmacology 209:135-138 (1991).
Skre et al. “A Twin Study of DSM-III-R Anxiety Disorders” Acta Psychiatrica Scandinavica 88:85-92 (1993).
Wang et al. “Possible Association of A Cholecystokinin Promotor Polymorphism (CCK36CT) With Panic Disorder” American Journal of Medical Genetics (Neuropsychiatric Genetics) 81:228-234 (1998).
Weissman et al. “The Cross-national Epidemiology of Panic Disorder” Arch. Gen. Psychiatry 54:305-309 (1997).
Hattori Eiji
Yoshikawa Takeo
Fredman Jeffrey
Riken
LandOfFree
Polymorphic DNAs and their use for diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphic DNAs and their use for diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic DNAs and their use for diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3368283